Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
29 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Auris Medical Holding AG - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Auris Medical Holding AG - Product Pipeline Review - 2014', provides an overview of the Auris Medical Holding AG's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Auris Medical Holding AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Auris Medical Holding AG including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Auris Medical Holding AG's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Auris Medical Holding AG's pipeline products Reasons to buy - Evaluate Auris Medical Holding AG's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Auris Medical Holding AG in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Auris Medical Holding AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Auris Medical Holding AG and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Auris Medical Holding AG - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Auris Medical Holding AG and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Auris Medical Holding AG Snapshot 4 Auris Medical Holding AG Overview 4 Key Information 4 Key Facts 4 Auris Medical Holding AG- Research and Development Overview 5 Key Therapeutic Areas 5 Auris Medical Holding AG- Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products- Monotherapy 8 Pipeline Products- Partnered Products 9 Partnered Products/Combination Treatment Modalities 10 Auris Medical Holding AG- Pipeline Products Glance 11 Auris Medical Holding AG- Late Stage Pipeline Products 11 Phase III Products/Combination Treatment Modalities 11 Auris Medical Holding AG- Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Auris Medical Holding AG- Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Auris Medical Holding AG- Drug Profiles 14 esketamine hydrochloride 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 XG-102 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 AM-102 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 AM-123 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Auris Medical Holding AG- Pipeline Analysis 19 Auris Medical Holding AG- Pipeline Products by Target 19 Auris Medical Holding AG- Pipeline Products by Route of Administration 20 Auris Medical Holding AG- Pipeline Products by Molecule Type 21 Auris Medical Holding AG- Pipeline Products by Mechanism of Action 22 Auris Medical Holding AG- Recent Pipeline Updates 23 Auris Medical Holding AG- Locations And Subsidiaries 27 Head Office 27 Other Locations & Subsidiaries 27 Appendix 28 Methodology 28 Coverage 28 Secondary Research 28 Primary Research 28 Expert Panel Validation 28 Contact Us 29 Disclaimer 29
List of Tables Auris Medical Holding AG, Key Information 4 Auris Medical Holding AG, Key Facts 4 Auris Medical Holding AG- Pipeline by Indication, 2014 6 Auris Medical Holding AG- Pipeline by Stage of Development, 2014 7 Auris Medical Holding AG- Monotherapy Products in Pipeline, 2014 8 Auris Medical Holding AG- Partnered Products in Pipeline, 2014 9 Auris Medical Holding AG- Partnered Products/ Combination Treatment Modalities, 2014 10 Auris Medical Holding AG- Phase III, 2014 11 Auris Medical Holding AG- Phase II, 2014 12 Auris Medical Holding AG- Preclinical, 2014 13 Auris Medical Holding AG- Pipeline by Target, 2014 19 Auris Medical Holding AG- Pipeline by Route of Administration, 2014 20 Auris Medical Holding AG- Pipeline by Molecule Type, 2014 21 Auris Medical Holding AG- Pipeline Products by Mechanism of Action, 2014 22 Auris Medical Holding AG- Recent Pipeline Updates, 2014 23 Auris Medical Holding AG, Other Locations 27 Auris Medical Holding AG, Subsidiaries 27
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.